Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, is collaborating with the Agency for Science Technology and Research’s (A*STAR) Institute of Molecular and Cell Biology (IMCB) in Singapore to form a research laboratory. Jointly operated by Tessa and IMCB, the facility will harness new preclinical technologies and provide capabilities to accelerate the discovery and development of the next generation of cell therapies.
The collaboration is focused on IMCB’s research expertise, including new humanized patient-derived-xenograft (PDX) and patient-derived-organoid (PDO) models. These models will be used to screen Tessa’s novel cell therapies and accelerate clinical development as well as enable the discovery of potential new therapeutic targets against cancer.
In addition, the laboratory will contribute other preclinical and clinical work, including product characterization studies and compiling data required for Investigational New Drug (IND) applications with the U.S. Food and Drug Administration (FDA) and other regulatory submissions.
The agreement marks Tessa’s second collaboration with IMCB, a research institute within A*STAR, Singapore’s lead government agency spearheading scientific discovery and innovation in the region.
(Source: Tessa Therapeutics)